Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pucciarelli, S.
Right arrow Articles by Lise, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pucciarelli, S.
Right arrow Articles by Lise, M.
Related Collections
Right arrow Chemotherapy
Right arrow Surgery

Annals of Surgical Oncology, Vol 7, Issue 1 38-44, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results

S. Pucciarelli, M. L. Friso, P. Toppan, A. Fornasiero, S. Carnio, E. Marchiori and M. Lise
Clinica Chirurgica II, Dipartimento di Scienze Oncologiche e Chirurgiche, Universita di Padova, Italy.

BACKGROUND: Adjuvant treatment for rectal cancer is still controversial. This study reports on overall survival and disease-free survival, toxicity, downstaging, and surgical morbidity in rectal cancer patients who received combined chemoradiation therapy followed by curative surgery. METHODS: Between 1993 and 1998, 51 patients (31 males and 20 females; median age, 60 years; range, 33-73 years) underwent chemoradiation therapy followed by radical surgery for middle and lower rectal adenocarcinoma. Criteria for giving preoperative radiotherapy (total 45 Gy in 25 fractions of 1.8 Gy/day for 5 weeks) and chemotherapy (5-fluorouracil 350 mg/m2/day and leucovorin 10 mg/m2/day, bolus on days 1-5 and 29-33) were an age younger than 75 years; an Eastern Cooperative Oncology Group performance status score of 0 to 2; and clinical preoperative stage II-III. Forty-three low anterior and eight abdominoperineal resections were performed. Median follow-up time was 29 (range, 3-63) months. RESULTS: Although grade 3 to 4 toxicity occurred in 14 cases (27.4%), all patients completed the planned adjuvant therapy. At pathology, a complete response was found in eight (15.7%) cases. Of the remaining 43 cases, 22 were stage I, 12 were stage II, and 9 were stage III. Five-year actuarial disease-free survival and overall survival rates were 86.4% and 85.5%, respectively. Whereas no local recurrences were found, 4 patients had distant metastases. Three patients died (1 of cancer-related causes), 45 are alive and disease free, and 3 are alive with disease. CONCLUSIONS: The combined preoperative chemoradiation approach used by us seems to improve the disease-free survival and overall survival of selected patients with rectal cancer. However, a longer follow-up time is required to confirm these preliminary results.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
H. Tulchinsky, E. Shmueli, A. Figer, J. M. Klausner, and M. Rabau
An Interval >7 Weeks between Neoadjuvant Therapy and Surgery Improves Pathologic Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer
Ann. Surg. Oncol., October 1, 2008; 15(10): 2661 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
I. Maretto, F. Pomerri, S. Pucciarelli, C. Mescoli, E. Belluco, S. Burzi, M. Rugge, P. C. Muzzio, and D. Nitti
The Potential of Restaging in the Prediction of Pathologic Response After Preoperative Chemoradiotherapy for Rectal Cancer
Ann. Surg. Oncol., February 1, 2007; 14(2): 455 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. Tulchinsky, M. Rabau, E. Shacham-Shemueli, G. Goldman, R. Geva, M. Inbar, J. M. Klausner, and A. Figer
Can Rectal Cancers With Pathologic T0 After Neoadjuvant Chemoradiation (ypT0) Be Treated by Transanal Excision Alone?
Ann. Surg. Oncol., March 1, 2006; 13(3): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele, M. L. Friso, S. Pucciarelli, S. Lonardi, L. Sartor, G. Fabris, E. D. L. Urso, P. Del Bianco, G. Sotti, M. Lise, et al.
A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer
Ann. Onc., July 1, 2005; 16(7): 1140 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Pucciarelli, C. Capirci, U. Emanuele, P. Toppan, M. L. Friso, G. M. Pennelli, G. Crepaldi, L. Pasetto, D. Nitti, and M. Lise
Relationship Between Pathologic T-Stage and Nodal Metastasis After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer
Ann. Surg. Oncol., February 1, 2005; 12(2): 111 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
F. Bozzetti, S. Andreola, D. Baratti, L. Mariani, S. C. Stani, F. Valvo, and P. Spinelli
Preoperative Chemoradiation in Patients With Resectable Rectal Cancer: Results on Tumor Response
Ann. Surg. Oncol., June 1, 2002; 9(5): 444 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. W. Onaitis, R. B. Noone, R. Fields, H. Hurwitz, M. Morse, P. Jowell, K. McGrath, C. Lee, M. S. Anscher, B. Clary, et al.
Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival
Ann. Surg. Oncol., December 1, 2001; 8(10): 801 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. Esposito, S. Pucciarelli, R. Alaggio, L. Giacomelli, E. Marchiori, G. A. Iaderosa, M. L. Friso, P. Toppan, L. Chieco-Bianchi, and M. Lise
p27kip1 Expression Is Associated With Tumor Response to Preoperative Chemoradiotherapy in Rectal Cancer
Ann. Surg. Oncol., May 1, 2001; 8(4): 311 - 318.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.